Neurocrine Biosciences (NBIX) EPS (Diluted) Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) EPS (Diluted) Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 65.33% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 5.88% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -394.16% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -12.15% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 105.88% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2,383.26% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -16.09% |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | -257.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,383.26% |
| Dec 31, 2025 | 50.82% |
| Sep 30, 2025 | 64.24% |
| Jun 30, 2025 | 70.13% |
| Mar 31, 2025 | -81.60% |
| Dec 31, 2024 | -32.01% |
| Sep 30, 2024 | 51.41% |
| Jun 30, 2024 | -34.36% |
| Mar 31, 2024 | 153.10% |
| Dec 31, 2023 | 62.50% |
| Sep 30, 2023 | 18.79% |
| Jun 30, 2023 | 639.15% |
| Mar 31, 2023 | -653.92% |
| Dec 31, 2022 | 1,306.85% |
| Sep 30, 2022 | 200.45% |
| Jun 30, 2022 | -140.83% |
| Mar 31, 2022 | -56.43% |
| Dec 31, 2021 | -102.10% |
| Sep 30, 2021 | 137.30% |
| Jun 30, 2021 | -46.59% |